PLATINIUM, released simultaneously in both Europe and Japan by LivaNova (formerly Sorin Group), will protect patients from avoidable replacement surgeries and the inherent risk of complications.

Upgrade to cardiac resynchronization therapy with a defibrillator (CRT-D) reduces morbidity and mortality and improves left ventricular (LV) reverse remodeling compared to an implantable ...

AMSTERDAM, the Netherlands—Among patients with heart failure with reduced ejection fraction (HFrEF), a previously implanted pacemaker or ICD, and a significant RV pacing burden, upgrading to a cardiac ...

Please provide your email address to receive an email when new articles are posted on . Among patients with nonischemic cardiomyopathy, women were less likely to die or have a ventricular event than ...

AMSTERDAM -- A cardiac resynchronization therapy (CRT) upgrade produced solid clinical benefit for patients with pacing-induced heart failure with reduced ejection fraction (HFrEF), the small BUDAPEST ...

The company identified 7 studies that incorporated a cost-effectiveness analysis. It did not rely on these economic studies for its model, but the structure of the de novo model is similar to that ...

Upgrade to cardiac resynchronization therapy with a defibrillator (CRT-D) reduces morbidity and mortality and improves left ventricular (LV) reverse remodeling compared to an implantable ...

The ENDURALIFE battery technology (Boston Scientific) is designed to extend the battery life of Boston Scientific cardiac resynchronisation therapy-defibrillator (CRT‑D) devices. CRT‑Ds are a ...

May 11, 2005 (New Orleans) — Poor renal function and the nonuse of certain heart failure medications were powerful predictors of early and late mortality in patients receiving cardiac ...

It's dangerous in medicine to make decisions based solely on what makes intuitive sense. At the European Society of Cardiology (ESC) Congress 2023, we learned from the BUDAPEST CRT trial that the ...